Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14908542 | 0.86 | CHRM2 (0.38) | SIGMAR1CHRNB2CHRNA4CYP3A4PIM1 | |
| SCHEMBL13966512 | 0.78 | SIGMAR1 (0.35) | SIGMAR1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL13975852 | 0.78 | SIGMAR1 (0.35) | SIGMAR1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL10140330 | 0.73 | MEN1 (0.44) | SIGMAR1HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL256336 | 0.72 | HTR2A (0.43) | SIGMAR1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL12905336 | 0.69 | HTR2A (0.41) | SIGMAR1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL16998410 | 0.69 | SIGMAR1 (0.48) | SIGMAR1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL13966514 | 0.68 | SIGMAR1 (0.35) | SIGMAR1CHRNB2CHRNA4CYP3A4 | |
| SCHEMBL13975828 | 0.68 | CHRM2 (0.36) | SIGMAR1CHRNB2CHRNA4CYP3A4CYP1A2 | |
| SCHEMBL929216 | 0.68 | CHRNB2 (0.47) | SIGMAR1HTR2AHTR2CHTR2BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9139613-B2 | Macrocyclic compounds and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-22 | — | — | US | disclosed |
| US-9119853-B2 | Sanglifehrin based compounds | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-01 | — | — | US | disclosed |
| US-20140234414-A1 | Novel Dosage Form | Abliva Ab (SE) | 2014-08-21 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234414-A1 | Novel Dosage Form | SI, RAB10, SAMM50 | SIGMAR1 2125/4885HTR2A 2389/4885HTR2C 3663/4885 |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | HAVCR2, RPL35, CD4 | SIGMAR1 3849/4885HTR2A 4716/4885HTR2C 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.